Logo

REVBW

Revelation Biosciences, Inc.

REVBW

Revelation Biosciences, Inc. • NASDAQ
$0.01 ▲ 25.00% (+0.00)
Market Cap $59241
52w High $0.01
52w Low $0.01
Dividend Yield 0%
P/E 0
Volume 5.90K
Outstanding Shares 5.92M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.943M ▼ $-1.907M ▲ 0% $-1.77 ▲ $-1.9M ▲
Q2-2025 $0 $2.461M ▲ $-2.444M ▼ 0% $-7.01 ▼ $-2.454M ▼
Q1-2025 $0 $2.095M ▲ $-2.051M ▼ 0% $-2.11 ▲ $-2.088M ▼
Q4-2024 $0 $1.754M ▼ $-1.726M ▲ 0% $-4.98 ▲ $-1.747M ▲
Q3-2024 $0 $1.797M $-2.242M 0% $-13.38 $-1.789M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.708M ▲ $12.856M ▲ $1.855M ▲ $11.002M ▲
Q2-2025 $5.174M ▲ $5.395M ▲ $1.569M ▲ $3.826M ▲
Q1-2025 $3.705M ▼ $3.97M ▼ $1.09M ▼ $2.881M ▼
Q4-2024 $6.499M ▼ $6.622M ▼ $1.914M ▼ $4.708M ▲
Q3-2024 $6.541M $6.74M $4.067M $2.674M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.907M ▲ $-1.589M ▲ $0 $9.124M ▲ $7.535M ▲ $-1.589M ▲
Q2-2025 $-2.444M ▼ $-1.919M ▲ $0 $3.389M ▲ $1.469M ▲ $-1.919M ▲
Q1-2025 $-2.051M ▼ $-2.794M ▲ $0 ▼ $0 ▼ $-2.794M ▼ $-2.794M ▲
Q4-2024 $-1.726M ▲ $-3.748M ▲ $17.689K ▲ $3.688M ▼ $-42.034K ▲ $-3.73M ▲
Q3-2024 $-2.242M $-9.257M $-17.688K $3.743M $-5.532M $-9.275M

Five-Year Company Overview

Income Statement

Income Statement Revelation Biosciences is still a classic early‑stage biotech story: no product sales yet and ongoing losses. All the reported periods show essentially zero revenue and continuing negative earnings, which is what you’d expect from a company funding research rather than selling approved drugs. The losses themselves look relatively small in absolute terms, but the very large swings in per‑share figures likely reflect capital structure changes such as reverse splits, not operational changes. In simple terms: the business is spending on development without any commercial income yet, and financial performance is entirely driven by R&D and overhead, not by a running product line.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a modest amount of cash and almost no other meaningful assets reported. There is no reported debt, which reduces financial pressure from lenders, but equity levels are thin and have fluctuated, suggesting the company’s capital base is fragile and highly dependent on external funding rounds. Overall, the balance sheet looks lean, cash‑constrained, and typical of a small, clinical‑stage biotech that must periodically raise new capital to keep moving its programs forward.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting ongoing research, clinical, and corporate expenses without offsetting revenue. There is essentially no spending on physical assets, so cash burn is almost entirely tied to running the business and the pipeline. Free cash flow is negative across the board, underscoring that the company is consuming cash rather than generating it. Sustaining the current strategy will likely require repeated access to capital markets or partnering, because internal cash generation is not yet a factor.

Competitive Edge

Competitive Edge Competitively, Revelation sits in a crowded and high‑stakes space—kidney disease and inflammatory conditions—but with a distinct scientific angle. Its lead program, Gemini, targets the innate immune system through TLR4 activation to rebalance inflammation, which is different from many existing therapies that broadly suppress immune activity or act on other pathways. The potential breadth of indications (chronic and acute kidney disease, surgical infections) and a focused intellectual property position give it some differentiation. That said, it is still an early‑stage player with no approved products, going up against much larger, well‑funded companies and alternative modalities, so execution risk and the ability to stand out clinically are key uncertainties.

Innovation and R&D

Innovation and R&D Innovation is the clear strength here. Gemini’s approach—reprogramming the innate immune response rather than simply blocking inflammation—is scientifically interesting and early clinical data in kidney disease has shown encouraging safety and biological activity signals. The same core technology could be applied to several inflammatory and infectious settings, giving the R&D platform multiple ways to create value if the mechanism continues to hold up in larger trials. However, all of this remains at an early proof‑of‑concept stage: the company still needs to run larger, longer, and more expensive studies, engage regulators on trial design, and demonstrate that biomarker improvements translate into real‑world clinical benefits for patients.

Summary

Overall, Revelation Biosciences is a very early‑stage, pre‑revenue biotech with an innovative but unproven immunology platform and a very light financial base. The income statement and cash flow show a straightforward pattern of ongoing losses and cash burn, typical for a company still in the clinical development phase. The balance sheet has little cushion and no debt, which limits interest burdens but heightens dependence on fresh capital. On the strategic side, the company’s differentiation comes from its TLR4‑based approach to rebalancing inflammation and the potential to apply one core technology across multiple kidney and infection‑related indications. The key opportunities lie in successfully advancing through upcoming clinical and regulatory milestones, while the main risks center on scientific uncertainty, trial outcomes, regulatory feedback, and the need to secure sufficient funding to complete the development path.